Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will FTC Shakeup Impact Pharma?

Executive Summary

With full slate of new commissioners FTC may expand focus to FDA regulatory issues; Commission has four cases against pharma companies in federal court and is fighting challenges to its authority to bring pay-for-delay suits.

Related Content

Impax Defeats FTC Pay-For-Delay Complaint, Helped By Status As Sole Marketer Of Generic Opana ER
Biosimilar/Brand Patent Settlements Need US Antitrust Review, PBM Says
FTC Scrutiny Of Profit Seeking In Drug Supply Chain In Fact-Finding Mode
Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition
Pay-For-Delay Settlements Decline In Wake Of Supreme Court Ruling
FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions
FTC Focus On Pay-For-Delay Deals Continues; Endo Agrees To 10-Year Abstention
FTC Faces Uphill Battle In AndroGel Pay-For-Delay Suit
FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene
Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts